Related Experiment Video

Updated: Apr 25, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

4.9K

Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure

Muhammad Hammadah1, Yiying Fan2, Yuping Wu2

  • 1Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Journal of Cardiac Failure
|August 17, 2014
PubMed

Insights

Higher ceruloplasmin (Cp) levels predict increased mortality risk in stable heart failure patients. Measuring serum Cp can help identify individuals with a heightened risk of death.

Area of Science:

  • Cardiology
  • Biochemistry
  • Clinical Medicine

Background:

  • Ceruloplasmin (Cp) is a copper-binding protein involved in inflammation.
  • Elevated Cp levels are linked to an increased risk of heart failure.
  • Current understanding of Cp's prognostic value in heart failure is limited.

Purpose of the Study:

  • To evaluate if serum Cp provides independent and incremental prediction of survival in stable heart failure patients.
  • To test the hypothesis that higher Cp levels are associated with increased mortality risk.

Main Methods:

  • Serum Cp levels were measured in 890 stable heart failure patients.
  • Patients were followed for 5-year all-cause mortality.
  • Statistical models adjusted for traditional risk factors and biomarkers like BNP and LVEF.

Main Results:

  • Higher Cp levels were associated with increased 5-year all-cause mortality.
  • Cp remained an independent predictor of mortality after adjusting for multiple clinical variables.
  • Adding Cp to risk models significantly improved prediction accuracy (net reclassification improvement of 9.3%).

Conclusions:

  • Serum ceruloplasmin is an independent predictor of mortality in heart failure patients.
  • Cp measurement can aid in identifying patients at higher risk of death.
  • Further research may explore therapeutic implications of Cp modulation.
Abstract

Keywords:
Heart failurebiomarkersceruloplasminoutcomes

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
1.2K
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
670
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
785
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
861